
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title Associate Director, Clinical Data Management
Reports to: Executive Director, Clinical Data Management
Location Remote
The AD, Clinical Data Management (CDM) is responsible for leading and overseeing clinical data management activities across assigned clinical studies to ensure the delivery of high-quality, regulatory-compliant, and inspection-ready clinical data. This individual will provide strategic and operational leadership for end-to-end data management activities from study start-up through database lock and submission support.
Operating in a fast-paced, growth-stage environment, the Associate Director will partner closely with Clinical Operations, Biostatistics, Statistical Programming, Clinical Development, Regulatory, Quality, and external vendors to drive efficient and scalable data management processes, standards, and technologies. This role will contribute to the evolution of Kyverna’s CDM infrastructure and operating model while supporting multiple studies across the clinical development portfolio.
The national salary range for this position is $175K to $195K USD annually. This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.